Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment ...

Zai Lab Limited (ZLAB) said it has reached a new strategic collaboration and global licensing agreement with MediLink Therapeutics ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has extended its collaboration with ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments.